Gilead Sciences to Present at Upcoming Investor Conference

On December 20, 2024 Gilead Sciences, Inc. (Nasdaq: GILD) reported that its executives will be speaking at the following investor conference (Press release, Gilead Sciences, DEC 20, 2024, View Source [SID1234649247]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

J.P. Morgan Healthcare Conference on Monday, January 13, 2025 beginning at 11:15 a.m. Pacific Time
The live webcast can be accessed at investors.gilead.com and the replay will be available for at least 30 days following the presentation.

Foresight Diagnostics to Present at 43rd Annual J.P. Morgan Healthcare Conference

On December 20, 2024 Foresight Diagnostics, Inc. ("Foresight") a leading diagnostics company specializing in the development of ultra-sensitive minimal residual disease (MRD) detection, reported that CEO, Jake Chabon, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 7:30am Pacific Time (Press release, Foresight Diagnostics, DEC 20, 2024, View Source [SID1234649248]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Foresight Diagnostics will be hosting meetings at the LifeSci Corporate Access Event from January 13-15, 2025, and will also be available for additional meetings on January 16. To schedule a meeting with the Company, please contact [email protected].

Phase I Clinical Trial Application of Novel Targeted Anti-Cancer Drug ZHB015 for Injection Approved by the NMPA

On December 20 2024, Zonhonbio reported its class 1 innovative biological drug, ZHB015 for injection, has received the "Clinical Trial Approval Notice" from China’s NAtional medical products administration (NMPA) (Press release, Zonhon Biopharma Institute, DEC 20, 2024, View Source [SID1234656086]). ZHB015 for injection is an original research and development by Zonhonbio, with completely independent intellectual property rights both domestically and internationally. It is a bispecific antibody drug developed using innovative targets and has been approved for use in advanced malignant solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Azitra, Inc. to Present at Biotech Showcase 2025 Alongside the J.P. Morgan Annual Healthcare Conference

On December 20, 2024 Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, reported the company will present at Biotech Showcase 2025 being held January 13-15, 2025 in San Francisco (Press release, Azitra, DEC 20, 2024, View Source [SID1234649233]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the presentation are as follows:

Event:

Biotech Showcase 2025

Date and Time:

January 13, 2025 at 3:00 p.m., PT

Location:

Hilton San Francisco Union Square (Yosemite C)

Participant:

Travis Whitfill, Chief Operating Officer

Registration:

Link

During the conference, members of Azitra’s management team will conduct one-on-one meetings with registered investors and potential partners, showcasing the company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones.

Biotech Showcase, produced by Demy-Colton and EBD Group, is a premier investor conference committed to creating a platform for private and micro-mid-cap biotechnology companies. It offers companies a unique opportunity to showcase their innovations and engage directly with investors and other biopharmaceutical executives.

BIO-TECHNE TO PRESENT AT THE 43rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

On December 20, 2024 Bio-Techne Corporation (NASDAQ: TECH) reported that Kim Kelderman, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 10:30 a.m. PST (Press release, Bio-Techne, DEC 20, 2024, View Source [SID1234649234]). A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne’s Investor Relations website at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!